欧倍纯® Human Albumin Grifols®
展商： Grifols基立福
原产国/地区：西班牙
主要成分：人血白蛋白 适应症： 1. 血容量不足的紧急治疗，遵循相关临床治疗规范。经晶体扩容后仍不能维持有效血容量或伴有低蛋白血症的情况下使用。 2. 显著的低白蛋白血症(≤ 30g/L)的治疗。 3. 新生儿高胆红素血症的治疗。 4. 急性呼吸窘迫综合征的治疗。 5. 用于心肺分流术、特殊类型血液透析、血浆置换的辅助治疗。 规格：10g/瓶 (20%, 50ml) 性状：本品为略粘稠、近无色、黄色、琥珀色或绿色澄明液体，不应出现浑浊。 Main Ingredients: Human Albumin Inidication: 1. Emergency treatment of hypovolemia, in accordance with the treatment specifications. It can be used to treat the conditions where the maintenance of effective blood volume failed after the crystalloids therapy or accompanied by hypoproteinemia. 2. Treatment of significant hypoalbuminemia ( 30g/L). 3. Treatment of neonatal hyperbilirubinemia. 4. Treatment of acute respiratory distress syndrome. 5. Adjuvant therapies for cardiopulmonary bypass, special type of hemodialysis, plasma replacement. Strength: 10g/vial (20%, 50ml) Properties: This product is slightly viscous, almost colorless, yellow, amber or green to brown clear liquid, there should be no turbidity.
展品详情
人血白蛋白是人体的正常组分，其最主要的生理功能是维持血液渗透压和转运功能。白蛋白稳定循环血容量，并携带激素、酶、药物、毒素等；静脉给药后在血循环中可被迅速而完全地利用。
欧倍纯®（Human Albumin Grifols®） 20%是一种含有20%人血白蛋白（重量/体积），用于单剂量静脉给药的无菌水溶液。本品等渗于四倍体积的正常人血浆。在本品的保质期内，溶液中铝含量不超过200 ㎍ /L。
本品使用时应依据患者的疾病严重程度、有效循环状况和蛋白质损失情况，结合临床治疗需要由医生决定给予的浓度、剂量、输注速率等。
Human albumin is the normal component of human body, its main physiological function is to maintain blood osmotic pressure and transport function. Human albumin can stable circulation blood volume, and carries hormones, enzymes, drugs, toxins, etc. It can be quickly and completely utilized in the blood circulation after intravenous administration.
Human Albumin Grifols® 20% is a sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). The colloid osmotic effect of this product is approximately four times that of normal human plasma. The aluminum content of the solution is not more than 200 micrograms per liter during the shelf life of the product.
The concentration, dose, infusion rate and so on of this product should be decided by the physician based on the severity of disease, effective circulation condition, proteins loss situation of the patient as well as the need for clinical treatment.